Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Smith Salley Wealth Management Purchases 1,771 Shares of Thermo Fisher Scientific Inc. $TMO
Smith Salley Wealth Management increased its holdings in Thermo Fisher Scientific Inc. by 3.1% in the third quarter, acquiring an additional 1,771 shares. This brings their total stake to 58,846 shares valued at $28.541 million, making TMO their 18th-largest position. Despite significant insider selling over the past 90 days, institutional ownership of Thermo Fisher Scientific remains high at 89.23%.
Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Generate Investment Management Ltd Invests $7.47 Million in Thermo Fisher Scientific Inc. $TMO
Generate Investment Management Ltd reported acquiring a new stake of 15,403 shares in Thermo Fisher Scientific Inc., valued at approximately $7.47 million during the third quarter. Institutional ownership of TMO now stands at about 89.23%, despite recent net selling by company insiders. Thermo Fisher Scientific has outperformed Q3 expectations and analysts have a "Moderate Buy" consensus rating with an average target price of $616.60.
Dec 31, 2025 • MarketBeat
NEUTRAL
Calamos Advisors LLC Grows Stock Position in Thermo Fisher Scientific Inc. $TMO
Calamos Advisors LLC significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.8% in Q3, now owning 147,700 shares valued at approximately $71.64 million. Despite this, company insiders have been net sellers, with CEO Marc N. Casper selling 17,104 shares and VP Lisa P. Britt selling 10,225 shares. The medical research company reported strong Q3 earnings, beating expectations, and authorized a $5.0 billion share buyback program.
Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Ascent Group LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO
Ascent Group LLC significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 39.8% in Q3, now holding 10,963 shares valued at approximately $5.32 million. This comes as Thermo Fisher Scientific reported strong Q3 earnings, beating analyst estimates, and announced a $5.0 billion share buyback program and a quarterly dividend of $0.43. Despite insider selling activity, the company maintains a "Moderate Buy" analyst rating with an average price target of $616.60.
Dec 31, 2025 • AD HOC NEWS
BULLISH
The Truth About Danaher Corp: Hidden Giant Every Investor Keeps Sleeping On
Danaher Corp (DHR) is presented as a "hidden giant" in life sciences, diagnostics, and environmental technology, contrasting with popular meme stocks. The article highlights its consistent performance, essential business model ("picks-and-shovels" for science), and strong fundamentals as reasons for its appeal to serious long-term investors. It concludes that DHR is a quiet game-changer for a diversified portfolio focused on quality and long-term structural trends, rather than a speculative, high-hype stock.
Dec 31, 2025 • AD HOC NEWS
BULLISH
The Truth About Danaher Corp: Hidden Giant Every Investor Keeps Sleeping On
Danaher Corp (DHR) is presented as a "hidden giant" in life sciences, diagnostics, and environmental tech, often overlooked by investors chasing meme stocks. The article highlights its consistent performance, essential business model ("picks-and-shovels" for science), and strong fundamentals as reasons for its appeal to serious long-term investors, contrasting it with trend-driven viral stocks. It emphasizes DHR's focus on recurring revenue and stability over flashy, short-term gains, positioning it as a foundational asset for a diversified portfolio.